• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

UBC Announces Real-World Evidence Generation Initiative

Article

New initiative from late-stage research and patient-support services organization aims to accelerate COVID-19 vaccine development.

UBC, a late-stage research and patient-support services organization, is announcing an offering to harness the power of real-world data (RWD) for rapid generation of insights into the safety and effectiveness of COVID-19 vaccines.

As vaccine manufacturers prepare for post authorization surveillance initiatives to generate outcome evidence in real-world settings, the ability to rapidly automate analysis of large-scale representative databases is essential.

The real-world data analyses will be made possible through a collaboration with companies such as global healthcare technology company Cerner Corporation and its Cerner Real-World Data, a national, de-identified data set including approximately 92 million patients from 90 health systems.

The integration of UBC’s analytical tools and epidemiologic expertise with real-world data enables researchers to customize and automate insights from the front lines of vaccine and healthcare delivery.

For more information, click here.

Related Videos